NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Everolimus plus Cisplatin may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: The purpose of this study is to test how effective combining Cisplatin chemotherapy
with Everolimus is in treating subjects with triple negative breast cancer who have residual
disease after chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Jenny C. Chang, MD
Collaborators:
The Methodist Hospital Research Institute The Methodist Hospital System